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by Robert L. Dixon, Ph. D.*
The purpose of this paper is to present
some of the more carefully studied aspects
of the preclinical toxicology of antineo-
plastic agents, and apply these findings (with
certain obvious cautions) to the area of en-
vironmental toxicology. Most of the studies
to be described here are the result of applied
toxicologic studies performed in support of
the clinical introduction of new chemicals in
the treatment of cancer. These considera-
tions are somewhat superficial and restricted
due to the fact that many questions regard-
ing the chemical mechanisms of action, and
the absorption, distribution, excretion, and
metabolism of these drugs are unanswered.
However, as valuable as this basic pharma-
cologic information will someday be to the
complete understanding of therapeutic and
toxic actions and effects, waiting is not a
realistic option. The cancer problem is now.
Thus, we are faced with the necessity of
defining problems and taking reasonable ac-
tions based on the currently available data
base; while, at the same time supporting,
appreciating, and being careful to nurture
more basic studies. The ideal situation is
obviously a blend of applied and basic re-
search. A similar situation most likely exists
in the area of Environmental Toxicology.
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Preclinical toxicology has been defined (1)
as an area of Economic Toxicology primarily
concerned with the development of drugs.
Anticancer agents, almost by design, are ex-
tremely toxic and potent, nonspecific, and
have a very low therapeutic index. The
major toxic effects of immediate concern are
usually acute or subacute effects, and be-
cause of the seriousness of the disease being
treated, probable long-term toxic hazards are
reluctantly accepted. The physicians using
these drugs are well aware of their toxic
potential, and clinical support facilities are
excellent. Considering these aspects it ap-
pears that the experimental (preclinical)
definition of the toxicity of anticancer drugs
is probably the most straightforward of any
clinically useful drug.
The toxicologist concerned with environ-
mental agents has almost the opposite situa-
tion. Environmental toxicology is concerned
primarily with the biological effects of
chemicals that are encountered by man
either incidentally because they are in the
atmosphere, or by contact during occupa-
tional or recreational activities, or by inges-
tion of food additives. When air is the
source of chemicals, it is obvious that ex-
posure is unavoidable, whereas exposure to
chemicals used in industry is determined by
industrial practices. With the increasing rate
of synthesis and the growing commercial use
of chemicals, it seems that no one is entirely
free of exposure to a variety of chemicals
capable of producing undesirable effects on
biologic tissues. The real and potential haz-
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to define, exposure levels are hard to quan-
titate, and acute toxicity is much less of a
concern than are long term risks such as
carcinogenesis and mutagenesis.
At the present time, almost half a million
products are used industrially. Toxicity data
are available on a few of these chemicals,
and Gerarde (2) has presented a partial clas-
sification of such chemicals. Chemicals may
be added to the feed of animals for thera-
peutic purposes or as pesticides. Each has
the potential of becoming part of man's
diet. Geiling and D'Aguanno (3) have listed
some of the drugs that are commonly added
to animal feed. The use of pesticides and
insecticides in agriculture also presents the
possibility of residues of these chemicals
being present when the food is consumed.
Chemical preservatives added to processed
foods become contaminants when the- food
is consumed. The study of the limitations
that must be observed in regard to food
additives, and the evaluation of safety from
harmful effects of such chemicals is also the
responsibility of the environmental toxicol-
ogist.
The toxicologic study of any chemical in-
volves essentially the same disciplines. These
are presented in Figure 1, and represent the
necessary expertise associated with any con-
sideration of a potential health hazard pre-
sent in the biosphere. Environmental
toxicology might therefore be described as
that branch of toxicology which deals with
incidental exposure of biologic tissue, and
more specifically in man; to the study of
chemicals that are basically contaminants of
his atmosphere, food, or water. This descrip-
tion includes the study of the causes, condi-
tions, effects, mechanisms, and limits of
safety of such exposure to chemicals.
Preclinical Toxicology of Anticancer Agents
The Laboratory of Toxicology of the
Chemotherapy Program at the National
Cancer Institute from which I recently trans-
ferred, is responsible for the preclinical
toxicology of new anticancer agents and
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FIGURE 1. Disciplines involved in toxicity studies of
chemicals.
investigates basic aspects of the patho-
genesis of drug-induced disease. The struc-
ture and organization of the Chemotherapy
Program has provided a large amount of
carefully recorded experimental and clinical
information dealing with the toxic effect of
these drugs. These data provide an informa-
tion base for a continuing evaluation of the
effectiveness of these experimental toxico-
logic studies in warning the clinician of
probable toxic effects in man. Special em-
phasis is placed on the qualitative (clinical
signs; chemical, hematologic, and pathologic
lesions) and quantitative (dose) predictive-
ness of laboratory animal for the human
situation. I woLuld like to present some of
the successes and failures experienced recent-
ly. Hopefully, it will be of interest to all
toxicologists and form the basis for further
discussion to compare and contrast these
findings regarding anticancer agents with
toxicologic problems conceming environ-
mental chemicals other than drugs.
The Laboratory functions to accomplish
the following goals concerning the toxicity
of new antineoplastic agents:
1. Establish defined levels of toxicity for
each new agent using both dogs and
monkeys.
2. Indicate the major organ toxicity in
both experimental species.
3. Evaluate the predictability of observed
toxicity.
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effects.
5. Compare the consistency of qualitative
and quantitative toxicity within and be-
tween experimental species.
6. Determine the influence of dosage
schedules on toxicity.
7. Alert the clinician to the possibility of
delayed drug toxicity.
8. Describe the etiologic aspects of drug-
induced toxicity as indicated by hem-
atologic, chemical, and histopathologic
findings.
9. Suggest a dose for initial Phase I clin-
ical trials.
In the past, confusion has surrounded the
use of "MTD" to indicate both a minimally
toxic dose and the maximum tolerated dose
of a drug. MTD was defined by Freireich
and his coworkers (4) as the highest dose
killing none of the dogs or monkeys treated.
At the same time, MTD was defined by the
toxicologists as the dose which produced
only minimal reversible toxicity, and this is
the definition used by Schein et al. (5). To
alleviate any further question regarding de-
fined levels of toxicity which must form the
basis for all quantitative comparison and
extrapolation, the following definitions of
levels of toxicity were established:
Highest Nontoxic Dose (HNTD): The
highest dose at which no hematologic, chem-
ical, clinical, or pathologic drug-induced
alterations occurred; doubling this dose
produces aforementioned alterations.
Toxic Dose - "Low" (TDL): The lowest
dose to produce drug-induced alterations in
hematologic, chemical, clinical, or pathologic
parameters; doubling this dose produced no
lethality.
Toxic Dose - "High" (TDH): The lowest
dose to produce drug-induced alterations in
hematologic, chemical, clinical, or pathologic
parameters; doubling this dose produces
lethality.
Lethal Dose (LD): The lowest dose to
produce drug-induced death in any animals
during the period of observation.
In addition to establishing the dose level
that produces the defined levels of toxicity
for each schedule tested, a figure to indicate
the slope of the dose-response is indicated.
After discussing the relative value and prob-
lems of a mathematically derived slope, it
was decided to use a ratio of the Lethal
Dose to the Highest Nontoxic Dose in a
manner similar to a therapeutic ratio. The
most common ratio of the LD to the HNTD
for anticancer agents is eight (drugs are tested
by halving or doubling the initial dose). A
lower number would indicate a steeper slope
and a more rapid increase from nontoxic to
toxic drug doses. A number larger than eight
would indicate a more shallow slope and a
more gradual increase from nontoxic to lethal
levels with an accompanying increased margin
of safety.
This approach using dose ratios can be
questioned due to the fact that the ratio of
two doses ignores the possibility of a non-
linear dose response curve. However, past
experience demonstrates that it usually takes
four dose steps (1-2-4-8) to achieve the four
levels of toxicity previously described which
range from nontoxic to lethal. Any variant
would be recognized quickly and further
investigated.
Defined levels of toxicity for environ-
mental chemicals would also be valuable.
After a quick review of existing toxicity
data for a variety of common environmental
chemicals, a couple of points became appar-
ent. It is difficult to find complete toxi-
cologic studies on environmental chemicals
in the literature. It also seems that all the
chemicals reviewed are potent in that lethal-
ity can be produced although most are rela-
tively much less potent than the anticancer
agents. The threshold dose for toxicity
(HNTD) varies greatly, but once the toxic
threshold is reached the dosage increments
between the HNTD and lethality are remark-
ably similar. These studies, of course, involve
acute or subacute toxicity studies which
probably explains the steep slope in going
from threshold to lethal doses. The defini-
tion of toxic levels for long term hazards is
a much more difficult matter, and requires
first an agreement on whether a threshold
October 1972 105dose even exists.
Standardized protocols are used at the
National Cancer Institute (NCI) to perform
the routine preclinical toxicology. Special
emphasis is placed on clinical signs, clinical
chemistry, hematology, and the proper ex-
amination of organs and tissues for patho-
logic lesions. Such protocols insure consist-
ency within and between research
laboratories. Of course, no single scheme of
operations can set a prior limit to the ob-
jectives of preclinical toxicologic studies, and
it is obviously inappropriate to set rigid
specifications or criteria which apply uni-
formly to all experimental drugs. Neverthe-
less, an attempt must be made to outline
basic procedures which should elicit ade-
quate and useful toxicologic data for a
critical evaluation of the probable toxic risks
involved during initial clinical trial or human
exposure. These procedures must obviously
be applied with judgment, and necessary
modifications are introduced as indicated by
preliminary findings. These protocols are
available from NCI, and have been described
previously (6).
The only points to make here in regard to
Environmental Toxicology are self-evident:
some standardization of toxicologic proce-
dures is essential here if complete (as
possible) studies are to be performed, in-
formation gathered from a number of differ-
ent laboratories, results compared, and
extrapolations made to humans. In this
regard I would suggest that a generalized
approach to environmental toxicology be
considered while realizing that the situation
with environmental chemicals and antineo-
plastic drugs are not entirely analogous (7).
The general aim would also be to insure
coordination and cooperation between the
various federal and state agencies involved.
In the toxicology area, such an approach
would seek to insure that the more essential
pharmacologic and toxicologic components
necessary for any evaluation of a chemical
are available. It is obviously rather early for
such planning in the environmental health
area as an optimal data base is not currently
available. Therefore, great care must be
taken so that any structuring of general ef-
forts or more specific toxicologic approaches
in regard to environmental health does not
in any way compromise the efforts of more
basic scientists who are currently involved in
building the essential data base, but whose
projects might not fit into some niche of a
"linear array". A broad outline of some im-
portant pharmacologic and toxicologic con-
siderations is presented in Table 1, and I will
refer to this in more detail later.
A great deal of effort has gone into the
evaluation of the predictiveness of experi-
mental studies in dogs and monkeys for
toxicities in man. This area is being continu-
ally reviewed, and the recent paper by
Schein and coworkers is an outstanding
documentation of the effort (5). These
workers documented the usefulness of dogs
and monkeys in predicting potential qualita-
tive drug toxicity in man by examining
retrospectively twenty-five anticancer agents
of diverse chemical and functional classifica-
tion. It was found that the large animal
screen served to alert the physician to a
major proportion of the total spectrum of
drug effects which were encountered during
the clinical use of a new chemical com-
pound. The dog and monkey correctly
predicted bone marrow depression, gastro-
intestinal disturbance, and hepatotoxicity
for each drug producing these effects in the
clinic. In the case of renal, cardivascular, and
neuromuscular toxicity, however, the large
animal screen failed in some instances to
predict these toxicities in man. Unfortunate-
ly, the correct predictions were accom-
plished at the expense of a high percentage
of false positives (animal positive; human
negative) which resulted from the necessity
of using severely toxic dose levels in order
to demonstrate all potential toxicities inher-
ent in any compound. Tables 2, 3, and 4
present data from this study which demon-
strate the efficacy of the dog alone, monkey
alone, and dog and monkey together as
predictors of organ specific toxicity in man.
It can be seen that the dog and monkey
each predicts about the same percentage of
true positives (animal positive; human posi-
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I. Chemical and physical aspects.
a. Analyze purity of chemical and identify
contaminants.
b. Determine methods for extraction from
biological material and subsequent
quantitation.
c. Synthesize necessary breakdown and/
or metabolic products.
d. Determine ionization constants and lipid
solubility.
e. Investigate structure-activity relation-
ships.
f. Analyze binding forces in chemical-
protein (receptor) interaction.
II. Absorption, distribution, and elimination.
a. Define routes of exposure (skin, lung,
gastrointestinal tract, etc.)
b. Determine apparent volumes of
distribution.
c. Assess binding of chemical to plasma and
tissue proteins.
d. Establish mechanisms of translocation
and determine storage depots.
e. Quantitate passage across biological
membranes (CNS, intestine, placenta).
f. Investigate routes of elimination (renal,
biliary, lungs, etc.).
g. Determine kinetics of uptake , distribu-
tion, and elimination for exposure by
various routes.
III. Biotransformation.
a. Determine fate of chemical.
b. Identify metabolites.
c. Establish sites of metabolism.
d. Indicate the chemical pathway of biotrans-
formation.
e. Establish the biological activity of
metabolites.
f. Consider chemicals or conditions which alter
metabolism.
g. Determine species differences and genetic
variations.
IV. Routine acute and subacute toxicology.
a. Establish dose-response relationships for
biological effects and toxicity.
b. Determine LD-50's for various species
using potential routes of exposure.
c. Indicate potency, toxicity, cumulative
effects, and margin of safety.
d. Investigate the incidence of hyposensitivity
and hypersensitivity.
e. Determine general pharmacologic profile
for chemical.
f. Investigate activation and suppression
of the immune response.
g. Determine sensitizing potential and basis
of chemical allergy.
h. Establish antidotal systems for intoxication.
V. Routine longterm toxicology
a. Determine functional lesions (sensory,
cardiovascular, neuromuscular, etc.).
VI. Special longterm toxic hazards.
a. Actions on fertility and reproduction.
b. Establish teratogenic potential.
c. Investigate mutagenesis.
d. Assess carcinogenic potential.
VII. Statistics.
a. Validity of experimental designs and
conclusions.
VIII. Classification and analysis of toxic effects.
IX. Current assessment of health hazard associ-
ated with chemical.
tive), the monkey produces fewer false
positives, but more false negatives (animal
negative; human positive). A major problem
is that our current model systems predict
the obvious, and often miss the unexpected
toxicity. Anticancer drugs are known to
October 1972 107Table 2.-Dog as a Predictor for Organ Specific Toxicity in Man* (5)
FN**
TPt FP§ TNII FN¶ TP+ FN No. of
Organ system (%) (%) (%) (%) compounds
Injection site 16 36 40 8 33 25
Integument 12 32 40 16 57 25
Cardiovascular 28 24 36 12 30 25
Respiratory 16 64 16 4 20 25
Bone marrow 80 12 0 8 9 25
Lymphoid 4 72 24 0 0 25
Gastrointestinal 92 8 0 0 0 25
Liver 52 44 4 0 0 25
Renal 32 56 4 8 20 25
Neuromuscular 24 60 12 4 14 25
*TP = true positive; FP = false positive; TN = true negative; FN = false negative.
$Toxicity observed in both dogs and man.
§Toxicity observed in dogs but not in man.
IlNo toxicity observed in dogs or man.
¶Toxicity not observed in dogs but recorded in man.
**Corrected false negative, an index of false negative prediction which analyzes for only those compounds
which produced the specific toxicity in man.
Table 3.-Monkey as a Predictor for Organ-Specific Toxicity in man* (S)
FN**
TPt FP§ TNII FN¶ TP + FN No. of
Organ system (%) (%) (% ) (%) compounds
Injection site 13 26 52 9 40 23
Integument 13 17 57 13 50 23
Cardiovascular 22 26 30 22 50 23
Respiratory 13 48 30 9 40 23
Bone marrow 83 13 0 4 5 23
Lymphoid 0 31 65 4 100 23
Gastrointestinal 74 9 0 17 19 23
Liver 52 35 13 0 0 23
Renal 35 48 13 4 11 23
Neuromusular 22 30 39 9 28 23
*TP = true positive; FP = false positive; TN = true positive; FN = false negative.
tToxicity observed in both monkeys and man.
§Toxicity observed in monkeys but not in man.
IlNo toxicity observed in monkeys and man.
¶Toxicity not observed in monkeys but recorded in man.
**Corrected false negative, an index of false negative prediction which analyzes for only those compounds
which produced the specific toxicity in man.
Environmental Health Perspectives 108Table 4. The Combination ofDog and Monkey as a Predictor for Organ-Specific Toxicity in Man* (5)
FN**
TPt FP§ TNII FN¶ TP + FN No. of
Organ system (%) (%) (%) (%) compounds
Injection site 16 36 40 8 33 25
Integument 24 36 36 4 14 25
Cardiovascular 36 32 28 4 10 25
Respiratory 16 76 4 4 20 25
Bone marrow 88 12 0 0 0 25
Lymphoid 4 76 20 0 0 25
Gastrointestinal 92 8 0 0 0 25
Liver 52 48 0 0 0 25
Renal 36 56 4 4 10 25
Neuromuscular 24 60 12 4 14 25
*TP = true positive; FP = false positive; TN = true negative; FN = false negative.
tToxicity observed in both animals and man.
§Toxicity observed in animals but not in man.
IlNo toxicity observed in animals and man.
¶Toxicity not observed in animals but recorded in man.
**Corrected false negative, an index of false negative prediction which analyzes for only those compounds
which produced the specific toxicity in man.
generally affect the bone marrow, lymphoid
tissues, gastrointestinal tract and less com-
monly to exhibit hepatic and nephro-
toxicity. Cardiovascular, pancreatic, central
nervous and sensory lesions are much less
common. The first group is almost always
predicted; the second group is too often
missed in the original preclinical study.
In regard to Environmental Toxicology,
the major points of these qualitative evalua-
tions are that the dog and monkey (and
probably the rodent) reliably predict for
many of the toxic effects of a chemical
administered, either intentionally or inad-
vertently, to man. To achieve the best
prediction, experimental dose levels must be
escalated to lethality, and a price in false
positives must be paid. In studying extreme-
ly high doses of environmental chemicals to
determine their acute toxic potential, the
distinction must be made between these
dose levels and the concentrations present in
the environment. However, the apparent
discrepancies found between experimental
doses of environmental chemicals needed to
cause acute or subacute effects, and the
chemical concentrations found in the en-
vironment should not discredit in any way
these basic studies. There is always the
possibility that as more is learned concerning
the shape of the dose-response curves, and
the nature of receptors in experimental
animals and man that some of the large
discrepancies between doses and exposure
levels for man which are so apparent today
might not be real tomorrow. Nevertheless,
generally accepted concepts of comparative
dose-response relationships and toxic
thresholds should restrain somewhat the over
zealous reporter (or scientist) looking for
headlines. Everyone agrees that better and
more reliable experimental test systems must
be sought from the ever expanding scientific
base to enable specific prediction of the
wide variety of possible toxicities for man
associated with chemical exposure.
Most toxicities associated with anticancer
drugs are reversible if detected early enough.
This fact emphasizes the need for reliable
clinical tests which will provide an early
warning of drug-induced morphologic or
functional changes. The obvious exceptions
to the above statement regarding reversibility
are immunologic sensitization and neurologic
damage, and one should also add terato-
genic, mutagenic and carcinogenic effects to
October 1972 109the list of nonreversible toxicities. In all
cases, these nonreversible toxicities are of the
greatest concern. Unfortunately this area too
is hobbled by inadequate predictive test
systems.
The relative doses of a chemical which
produce toxicity or lethality must be con-
tinually re-evaluated. To assess these quantita-
tive aspects of drug toxicity, the data
compilation by Freireich et al. (4) is useful.
Toxicity data for small animals (mouse, rat,
and hamster), large animals (dogs and mon-
keys), and humans were gathered, placed on
a reasonably similar basis, and compared
quantitatively. Each animal species and all
species combined were used to predict the
toxic doses in man based on milligram per
square meter of body surface area (mg/M2).
The experimental animal text systems used
to evaluate the toxicities of potential anti-
cancer drugs correlate remarkably well with
the results in man. Figure 2 presents a repre-
sentative comparison of toxicity data on
anticancer agents for the mouse, rat, dog,
monkey and man. One can see that when
these data are expressed on a mg/M2 basis
there is rather good agreement between the
doses which cause toxicity in experiment
animals and man. However, the mg/M2 is
most useful when extrapolating toxicity data
for small animals to larger animals or man. It
appears to be much less useful when extrap-
olating toxicity data derived from dogs and
monkeys to man. This is most likely due to
the variability of the experimental data, and
the relatively small conversion factors neces-
sary to convert mg/kg doses in dogs and
monkeys. The body surface area conversion
factor is, of course, used in a number of areas
in physiology and medicine, and has been
discussed often in relation to drug dosage.
The usefulness of this type of dosage extrap-
olation to the toxicity of environmental
agents is largely unexplored due to the
problems of demonstrating or quantitating
toxicity in man.
Valuable lessons in regard to the effect of
dosage schedules on therapeutics response
and toxicity have been learned from the
work of Skipper and coworkers and others
(8). The principal objective of schedule
dependency antitumor testing in rodent
tumor models is to obtain information on
optimal conditions of drug use for designing
toxicologic studies in large animals and,
ultimately, for use by clinicians. Schedule-
dependency studies may also furnish leads
for uncovering biochemical sites of action.
The increasing awareness of the relationship
between drug effects and phases of the cell
cycle suggests that animal studies relating
dose schedule to the toxicology, pharma-
cology, and biochemical actions of the drug
and to the growth kinetics of malignant and
normal cells can establish important princi-
ples for improving clinical treatment. In
addition to the kinetics of cell proliferation,
the sites of drug action at the molecular
level, and the maximum drug concentration
(c) and the time (t) that an effective chem-
ical level is maintained at the target site are
also important. Lessons learned from experi-
mental chemotherapy are valuable in
toxicology.
Various treatment schedules are necessary
to assess the toxicity of drugs which have
demonstrated specific schedule sensitivity
during experimental therapeutic tests with
transplantable tumors. Following tumor in-
oculation, new drugs are routinely tested
utilizing a variety of treatment schedules.
A comparison of the optimally effective
dose (LD-10) and the increase in survival
times for cytosine arabinoside (NSC 63878)
is presented in Table 5. It is obvious that
very low doses administered every three
hours on days 1, 5, and 9 is the most
effective schedule. This treatment regimen
resulted in a four fold increase in life span,
and 70% long-term survivors. Similar dramat-
ic changes in toxicity are associated with
various schedules, and some of these data
are presented in Table 6. Total doses which
result in lethality for ten percent of the
mice are presented. It can be seen that treat-
ment every three hours, essentially the op-
timal therapeutic schedule, is the most toxic.
Unfortunately, the cell turnover time for the
target tumor and normal tissues is not very
different. The serum half-time for cytosine
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Arabinoside (8)
Ip treatment Optimal dose ILS T
schedule t (mg/kg/injection) (%)
Day 1 only 2312 33
q3h, Day 1 only 23 78
Days 1-9 39 100
Days 1, 5, 9 2313 128(1/10)
q3h, Days 1, 5, 9 14,23 >400(7/10)
t L1210 leukemia inoculated intraperitoneally on
day 1 in BDF1 mice.
T Increased life span; number of 45 day survivors
shown in parentheses.
arabinoside is about 20 minutes (longer for
very high doses), and the short term treat-
ment dose needed to -produce lethality is
very high. With a drug like this, very high
serum concentrations are tolerated for rela-
tively short period of twelve hours or less if
the treatment is not repeated too soon. If
the treatment is continued for 24 hours or
more, toxicity is much greater than cumula-
tive when compared to exposures of 12
hours or less. Continued exposure of 24, 48,
72 and 96 hours provides almost cumulative
toxicity. Interestingly, treatment intervals of
48-96 hours allow for very significant tissue
recovery in the mouse. Therefore, when the
experimental antitumor activity indicates
schedule dependency, the toxic effects of
prolonged drug levels by either infusion or
repeated injection are evaluated. These
dramatic effects of treatment schedule on
drug toxicity must also warn the environ-
mental toxicologist to be alert to sometimes
startling effects as a result of exposure time,
especially in the toxicity areas dealing with
effects of cell replication or differentiation.
Following acute or subacute drug treat-
ment, observation periods of at least 45 days
are necessary to insure an accurate evalua-
tion of the anticancer agent's potential for
delayed toxicity. The nitrosourea anticancer
agents produce life threatening toxicity
many weeks after a single treatment in both
laboratory animals and man. Delayed organ
toxicity in preclinical studies must always
alert the physician to this clinical possibility.
However, the clinical delayed toxicity might
be associated with a different organ system
than that observed in dogs or monkeys.
Delayed effects of acute or subacute ex-
Table 6. Toxicity of Cytosine Arabinoside to the BDF1 Mouse (on a Total Dose Basis)
When Administered According to Different Schedules (8)
Total Dose
Approx. Period Interval Between End
Schedule of Rx (hrs) Doses (hrs) mg/m2 Point
Single dose Single dose 9,000 LD10
q3hrs (x 3) 6 3 11,000 LD10
q2.5hrs (x 4) 7.5 2.5 >3,000 LD10
q3hrs (x 8) 24 3 560 LD10
q3hrs (x 16) 48 3 700 LD10
q3hrs (x 24) 72 3 750 LD10
q3hrs (x 32) 96 3 800 LD10
qd (x 6) 120 24 3,240 LD10
qd (x 15) 340 24 1,500 LD10
q2d (x 8) 340 48 15,000 LD10
q4d (x 4) 300 96 21,000 LD10
Environmental Health Perspectives 12posure to environmental chemicals, although
not exactly analogous, are probably the
problem that needs most serious considera-
tion. Teratogenic, mutagenic, and carcino-
genic toxicities fit this definition. Of major
concem recently, have been reports of
vaginal cancer in young girls years after their
mother was exposed to diethylstilbesterol
during pregnancy. This is a unique example
of delayed toxicity.
To be most effective, reports of toxi-
cology must move away from purely descrip-
tive accounts to a careful evaluation of the
hematologic, chemical, and histopathologic
findings in a best attempt to elucidate the
genesis and subsequent development of the
toxic state using available test methods. In
other words, toxicology must utilize the re-
sults from a number of static parameters to
start to resolve the complexities and obscur-
ities of the drug-induced disease. The
ultimate goal of the toxicologist must be an
understanding of the total mechanism of
toxic effect. A more complete knowledge of
mechanisms would hopefully allow for an
early prediction of subsequent physiologic
and pathologic alterations. To a degree, the
study of anticancer agents has partially
reached this point. Especially with alkylating
agents and antimetabolites, the strong, but
still incomplete, information base allows one
to predict fairly accurately the toxic effects
of most new drugs. Almost all of the unex-
pected toxicologic problems with new anti-
cancer agents are associated with new
categories of drugs (enzymes, heavy metals,
etc.) that have yet to achieve the same
degree of appreciation.
Obviously, it takes time to develop a base
of understanding conceming the mechanisms
of toxicity of a chemical; and that it is a
continuing process. This must also be the
goal of Environmental Toxicology, and the
descriptive information must be gathered in
a complete manner to facilitate the correla-
tion of biochemical and functional effects.
The detailed preclinical and clinical
studies of anticancer drugs have facilitated
the continuing evaluation of the predictive-
ness of preclinical investigations. I have
already mentioned important studies of the
quantitative and qualitative correlation be-
tween experimental animals and man (4,5).
The actual extrapolation of these data to
man for an untested chemical is one impor-
tant test of these experimental studies. How-
ever, the scientific value of experimental
studies does not rise or fall on the ability of
predictions made today from experimental
animals to be immediately verified by the
present clinical testing techniques. Such a
verdict would overlook the many problems
which still exist in understanding interspecies
differences in pharmacokinetics. Often with
better and more complete information,
previous poor prediction will be explained in
terms of the accessibility of a chemical to a
particular receptor. The final evaluation of
predictiveness must always await a compari-
son of comparable chemical concentrations
reaching comparable receptors.
The Laboratory of Toxicology has recent-
ly carefully examined the qualitative rela-
tionships between toxic doses of antitumor
agents in large animals and man (6). We have
extended the data of Freireich et al. (4) and
Schein et al. (5) by using essentially a probit
transformation to present the cumulative
distribution of antineoplastic drugs when the
ratio of toxic doses in dogs and/or monkeys
are compared to man. The individual toxic
dose ratios were considered to be members
of a normalized cumulative distribution. Any
drug's dose ratio can then be associated with
a cumulative fraction of the total sample of
ratios. For instance, half of the ratios would
be less than 50% and half greater. The
cumulative fraction may be considered
numerically equivalent to the probability
that a given dose will exceed the clinical
tolerated dose and thus provide an estimate
of the clinical risk of an untried clinical drug
candidate based on the animal data and the
pattern of relationships of similar drugs.
Thus, the cumulative fraction is plotted
against the ratio of the clinic dose to the
animal toxic dose, and each point represents
a different anticancer agent. If the mean ratio
of clinical toxic dose to animal toxic dose
was 1 (perfect predictability) then, depend-
October 1972 113ing on variation, one would expect half of
the drugs to be less toxic to humans and
half to be more toxic based on the animal
data. A representative plot of this type of
data is presented in Figure 3.
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FIGURE 3. Cumulative distribution of clinical
MTD: animal MTD ratios of antitumor drugs (6).
Using this system of analysis, quantita-
tive comparisons can be made between
experimental species and man; and the most
effective expression of dose (mg/kg or
mg/M2) can be determined. A point of par-
ticular interest is the probability of exceed-
ing a dose ratio of 0.1, or 1/10 of the toxic
dose in the most sensitive experimental
animal species. This derivation is commonly
used to establish the initial clinical doses for
a new drug. A more recent innovation is the
proposal that initial clinical doses be derived
as one-third of the animal tolerated dose
based on mg/M2. These data are presented
in Table 7. A dose one-tenth that of the dog
mg/kg tolerated dose carries a risk of 4% of
exceeding the clinical tolerated dose; the
corresponding risk associated with monkey
data is 9%. When one-third of the dose on a
mg/M2 basis is used, this type of analysis
indicates an equivalent risk associated with
monkey and dog data of about 10%; about
double that of using one-tenth the mg/kg
tolerated dose and ten times that of using
one-tenth of the mg/M2 dose. These studies
allow one to determine statistically the toxic
risk associated with any extrapolation from
experimental animal data in the selection of
the initial human dose. There is no question
that some level of risk must be accepted in
the selection of the initial clinical dose in
order to insure that large numbers of seriously
ill patients do not receive ineffective drug
levels. On the other hand, the dose must not
be so high that the patient is subjected to
serious toxic hazards. Therefore, two points
are clear; 1) a reasonable level of clinical risk
must be defined and accepted by the clin-
ician, and 2) it must be recognized that
statistically with any risk level selected,
eventually a certain percentage of drugs will
be introduced into the clinic at doses which
will produce toxicity. The difficult question
remains-what level of risk is acceptable?
Some level of risk must also be accepted
in regard to environmental chemicals based
on the benefits of the chemical to man.
Obviously, the acceptable risk level must be
many logs lower than that associated with
Table 7. Clinical Risk in Extrapolating Dog and Monkey Data toMan (6)
Clinical risk at
Predicting Dosage Regression mean ratio
species units (MTD clinical/MTD preclinical) 1/10 MTD 1/3 MTD
Dog mg/kg 0.86 3%
mg/m2 1.5 7%
Monkey mg/kg 0.5 12%
mg/m2 1.4 11%
Environmental Health Perspectives
10
14the introduction of a new anticancer agent.
However, the problems are the same in each
case. That is; reliable model test systems
must be produced, toxic effects demon-
strated, and extrapolation made from experi-
mental species to man. At that point, the
same question remains-what level of risk is
acceptable?
A Blend of Applied and Basic Research
As mentioned previously, the evaluation
of the toxic effects of environmental chem-
icals presents special challenges. Toxic
potentials are difficult to define, exposure
levels are hard to quantitate, exposure is
unintentional, readily apparent toxic effects
in humans are rare, and acute toxicity is
much less of a concern than are long term
risks such as carcinogenesis and mutagenesis.
The lack of a carefully directed overall
approach to environmental toxicology has
produced too little solid information, and
too many data from experiments inade-
quately designed to yield the maximum
benefit. I feel the scientific predictive base
for environmental toxicology needs strength-
ening in both approach and methodology to
enable one to use animal studies to predict
potential toxicologic problems and assesstheir
risk to human health.
With so many serious problems involving
drugs and other chemicals affecting the
health of living organisms, a way must also
be found to attract the best trained invest-
igators into applying their special talents to
a study of the broad, basic underlying
mechanisms of chemical toxicity. The newly
graduated Ph.D. faces a dilemma. Through-
out the years of graduate training, the
chastity and purity of basic science are em-
phasized. The subject of his dissertation is
usually very narrow, suggested by an advisor
as an extension of his own laboratory
interests, and requires years of in-depth
study. He often inherits experimental tools
and methods that are well developed
and understood, and the application of the
problem is secondary. His graduate training
experience leads the new graduate to seek a
first position where he can apply familiar
methods to extend the observations made
during his dissertation work. Thus, too many
scientists select some very narrow aspect of
an overall toxicologic problem, and pursue it
without enough concem for the total pic-
ture. Studies often represent the application
of analytical or biological test methods al-
ready operating in a laboratory, into which
are randomly fitted a series of environmental
chemicals. These bits and pieces of informa-
tion obviously represented good intentions
and a substantial effort in time and re-
sources. However, very important basic
toxicologic aspects are often unexplored.
The problem is lack of coordination. It is
impossible to construct a clear picture of the
hazard associated with many environmental
chemicals. It is as if the pieces of a puzzle
are fitted together at random rather than
being interlocking parts of a potentially
serious problem.
The problem of basic vs. applied research
must be resolved. I share with the basic
researcher the fear that things could move to
the point where some research czar would
direct the selection of the research area and
detail of the experimental approach. How-
ever, some attempt to coordinate (not dic-
tate) areas of research should not be rejected
as quickly.
The recent Conference on Polychlorinated
Biphenyls (PCBs) (9), and the current review
of the potential hazards to human health of
nitrilotriacetate (NTA) (10), demonstrate the
incomplete toxicologic picture available
when one attempts to review the available
literature in an attempt to establish the risk
or hazards associated with chemicals already
in the environment. Dr. Nelson summarized
the PCB conference and presented a series of
items urgently needing further clarification
(11). These points included the areas of en-
vironmental transport, distribution, occur-
rence, and alteration. In addition he called
attention to needed studies to clarify issues
of comparative metabolic patterns by species
which might account for some of the species
variability in regard to toxicity. In regard to
the mechanism of toxic actions Dr. Nelson
October 1972 115suggests, "Rather than to hastily examine
the effects of PCB's on a myriad of in vitro
test systems, it would seem wiser that these
studies be carefully planned as aids to under-
standing the observed course of PCB poison-
ing in the intact animal". Put another way,
there is an immediate need for a coordinated
approach to environmental toxicity starting
most often with the whole animal, and then
moving to the test tube to insure that pieces
of the problems are produced which help
most to resolve them.
Table 1 lists broadly some of the more
obvious areas of investigation for any chem-
ical released to the environment. Questions
concerning chemical and physical aspects;
absorption, distribution and elimination; bio-
transformation; routine acute and subacute
toxicology; routine long term toxicology;
special long term hazards; statistics; and the
classification and analysis of toxic effects are
indicated. The surprising thing is how often
concern is associated with an environmental
chemical that has been randomly studied for
years without producing even half of this
basic information. My point is only this,
each of these areas first requires the estab-
lishment of the general information which
then should be extended by more in-depth
studies to resolve basic mechanisms of
action. I think this "first-step first" ap-
proach will also hasten the development of
the information base necessary to produce
better predictive systems.
Conclusions
The structured approach to the experi-
mental and clinical study of anticancer
agents has produced a background of care-
fully gathered information which is available
for analysis. Questions regarding the effec-
tiveness of experimental animal studies to
predict chemically induced toxicity in man
can be asked and partially answered. This
organized program has not seriously com-
promised basic studies, but has brought the
"pure" basic scientist closer to his fellow
scientist charged with facing the more im-
mediate problems. There is obviously a need
for both undertakings. Environmental
Toxicology is also in need of a coordinating
program to assist the gathering of informa-
tion conceming the effects of chemicals on
human health. The main goals of such a
structuring would be greater completeness
for the toxicologic information gathering
process, and would provide "whole animal"
observations which would be extended by
more basic studies of mechanisms. This
approach should speed the development of
reliable predictive test systems, and present a
much better toxicologic picture for the eval-
uation of biologic hazards associated with
environmental chemicals.
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